
There is currently a “significant interest” in a collaboration concerning Bavarian Nordic’s candidate drug against prostate cancer, the vaccine prostvac, says Chairman of the board, Asger Aaamund, who is certain that the shareholders will someday thank the company’s management for the chosen strategy.
“We do not need a Prostvac partner right now, but Bavarian Nordic cannot take on the task of marketing Prostvac globally, and sooner or later we will obviously have to choose a partner in order to share the remaining development costs and to ensure a strong international market position,” Asger Aamund points out to Medwatch.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app